RT @declangmurphy: @SiskaVB @EveraertsW @piet_ost @shanekronos It’s quite amazing!! PLND appears to have disappeared from the updated Pros…

@declangmurphy @EveraertsW @piet_ost @shanekronos So … I indeed cannot seem to find a recommendation anymore in favor of PLND in the new guidelines 😮 I must admit I am a bit confused, what should we fight against now 🤷‍♀️😁

RT @uretericbud: 🔬💊 #TherapeuticNodeYield ➡️ #WillRogers 🤠 + #BiasMirage 🔮 as long anticipated @KBGinsburg #ASCO23

RT @uretericbud: 🔬ePLND in #BladderCancer 🏥 😞 More harm. ❌Zero benefit 📚Level I evidence from @SWOG👩‍⚕️👨‍⚕️ (t…

@DrDeanElterman @MaartenAlbersen @MikkelFode @faysal_a_yafi @cgratzke Damn, missed you at EAU!!

RT @dr_coops: ProtecT 15 yr: ⁦@Freddie_Hamdy⁩ taking on misconceptions, and conclusions. #eau23 Thoughts #pcsm??

RT @muratakand06: Check out our latest paper on "Quality Control Indicators for TURBT" #bladdercancer @EurUrolOncol

RT @LambAlastair: 15yr f/u for #ProtecT_Trial just out! •n=1610 •1/3 IR or HR by NCCN criteria •n=45 DS deaths (AM17:RP12:RT16) •n=104 mets…

@LambAlastair @BAUSurology @Freddie_Hamdy @NEJM @NDSurgicalSci @OxfordMedSci @dr_coops @SigridCarlsson @BJUIjournal @OxfordCancer @JimCatto @LabBryant So 62% of active treatment in AS group and still double risk of mets. That’s not reassuring (if avoiding mets would be the goal of course).

RT @LambAlastair: Guess this is key slide from Freddie's talk. It's given me a bit of an existential crisis over past 36hrs Should we appr…

RT @andries_c: Lymphedema after prostate cancer treatment? For many, it remains the forgotten vascular disease. 👉 Find out in our systemati…

RT @urotoday: When low-volume on conventional imaging goes into high-volume on next-generation imaging in #mHSPC - treat like low-volume. #…

RT @_ShankarSiva: Late breaking abstracts #ASTRO22 - @ChadTangMD EXTEND trial; oligometastatic #prostatecancer. Intermittent ADT + SABR ver…

RT @achoud72: @Prof_Nick_James on the association between volume & radiotherapy in #metastaticprostatecancer Is 4 the magic no for mets? Ho…

Just when you thought to grasp oligo-metastatic disease …@juliarmurray helping to see the light #PROSCA22

RT @achoud72: D2 #PROSCA22 in beautiful Athens @Silke_Gillessen outlines the evidence for #docetaxel in #mHSPC Is volume of disease import…

Amit Bahl warning to perform imaging in mCRPC even when PSA is stable. #PROSCA22

@AlbertoBossial gives us surgeons an important task : organize some phase III trials like we do 😁 #PROSCA22

Some Stampede high risk patients might be cured with surgery alone instead of ‘suffering’ 2 years of intensified hormonal treatment. #PROSCA22 @joniau excellent talk

@Achard_Verane Very clear talk at #PROSCA22 PSMA in BCR setting is interesting but creates a lot of new questions!